» Articles » PMID: 38725586

Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Kidney Transplant Recipients: A Large Single-Center Experience

Overview
Publisher Wiley
Specialty Critical Care
Date 2024 May 10
PMID 38725586
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Kidney transplant recipients (KTRs) are a vulnerable immunocompromised population at risk of severe COVID-19 disease and mortality after SARS-CoV-2 infection. We sought to characterize the post-infection sequelae in KTRs at our center.

Methods: We studied all adult KTRs (with a functioning allograft) who had their first episode of SARS-CoV-2 infection between 04/2020 and 04/2022. Outcomes of interest included risk factors for hospitalization, all-cause mortality, COVID-19-related mortality, and allograft failure.

Results: Of 979 KTRs with SARS-CoV-2 infection, 381 (39%) were hospitalized. In the multivariate analysis, risk factors for hospitalization included advanced age/year (HR: 1.03, 95% CI: 1.02-1.04), male sex (HR: 1.29, 95% CI: 1.04-1.60), non-white race (HR: 1.48, 95% CI: 1.17-1.88), and diabetes as a cause of ESKD (HR: 1.77, 95% CI: 1.41-2.21). SARS-CoV-2 Vaccination was associated with decreased risk of hospitalization (HR: 0.73, 95% CI: 0.59-0.90), all-cause mortality (HR: 0.52, 95% CI: 0.37-0.74), and COVID-19-related mortality (HR: 0.47, 95% CI: 0.31-0.71) in the univariate and multivariate analyses. Risk factors for both all-cause and COVID-19-related mortality in the multivariate analyses included advanced age, hospitalization, and respiratory symptoms for hospital admission. Furthermore, additional risk factors for all-cause mortality in the multivariate analysis included being a non-white recipient and diabetes as a cause of ESKD, with being a recipient of a living donor as protective.

Conclusions: Hospitalization due to COVID-19-associated symptoms is associated with increased mortality. Vaccination is a protective factor against hospitalization and mortality.

Citing Articles

Long-term follow-up of kidney transplant recipients admitted to a tertiary care transplant center with SARS-CoV-2.

Zona E, Gibes M, Jain A, Smith J, Garonzik-Wang J, Mandelbrot D World J Virol. 2024; 13(2):95273.

PMID: 38984080 PMC: 11229845. DOI: 10.5501/wjv.v13.i2.95273.

References
1.
Massie A, Werbel W, Avery R, Chiang T, Snyder J, Segev D . Quantifying excess deaths among solid organ transplant recipients in the COVID-19 era. Am J Transplant. 2022; 22(8):2077-2082. PMC: 9111343. DOI: 10.1111/ajt.17036. View

2.
Mackenna B, Kennedy N, Mehrkar A, Rowan A, Galloway J, Matthewman J . Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform. Lancet Rheumatol. 2022; 4(7):e490-e506. PMC: 9179144. DOI: 10.1016/S2665-9913(22)00098-4. View

3.
Parajuli S, Garonzik-Wang J, Astor B, Aziz F, Garg N, Welch B . Twelve Thousand Kidney Transplants Over More Than 55 Y: A Single-center Experience. Transplant Direct. 2024; 10(2):e1575. PMC: 10803012. DOI: 10.1097/TXD.0000000000001575. View

4.
Elgendy I, Pepine C . Why are women better protected from COVID-19: Clues for men? Sex and COVID-19. Int J Cardiol. 2020; 315:105-106. PMC: 7211570. DOI: 10.1016/j.ijcard.2020.05.026. View

5.
Tucker M, Azar M, Cohen E, Gan G, Deng Y, Foppiano Palacios C . Evaluating clinical effectiveness of SARS-CoV-2 vaccine in solid organ transplant recipients: A propensity score matched analysis. Transpl Infect Dis. 2022; 24(4):e13876. PMC: 9348300. DOI: 10.1111/tid.13876. View